Langhua Pharmaceutical

Viva Biotech announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan has been completed.

FAST NEWS: Viva Biotech completes Langhua Pharma buyout

The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…

Recent Articles

RELATED ARTICLES

  1. Henlius Bio
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  2. Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  3. Cancer drug maker Genfleet joins Hong Kong IPO influx
  4. Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva